Current Trials
ECHO Open to Accrual Clinical Trials
Updated: 09/04/2024
| Bladder / Urothelial IMMU-132-06 A Phase II Open-Label study of IMMU-132 in Metastatic Urothelial Cancer after failure of Platinum-Based regimen or Anti-PD-1/PD-L1 based Immunotherapy Breast ML43171 A Phase III, randomized, Open-Label, multicenter study evaluating the efficacy and safety of Giredestrant plus Everolimus compared with Exemestane plus Everolimus in patients with estrogen receptor-positive, HER2-Negative, locally advanced or Metastatic Breast Cancer WO43919 / INAVO121 A Phase III, Multicenter, Randomized, Open-Label Study Evaluating the efficacy and safety of Inavolisib plus Fulvestrant versus Alpelisib plus Fulvestrant in patients with Hormone Receptor Positive, HER-2-Negative, PIK3CA mutated, locally advanced or Metastatic Breast Cancer who progressed during or after CDK4/6 Inhibitor and Endocrine combination therapy Colorectal Metastatic WO42758 / INTRINSIC A Phase I/Ib Global, Multicenter, Open-Label Umbrella Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients with Metastatic Colorectal Cancer (INTRINSIC) Lung HLX10-005-SCLC301-E (Astride) A Randomized, Open-Label Study of HLX10 plus Chemotherapy (Carboplatin- Etoposide) in comparison with Atezolizumab plus Chemotherapy in Previously Untreated US Patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC) (Astride) HLX10-020-SCLC302 A Randomized, Double-Blind, International Multicenter, Phase III Study to Evaluate the Anti-Tumor Efficacy and Safety of HLX10 (Recombinant Humanized Anti-PD-1 Monoclonal Antibody Injection) or Placebo in Combination with Chemotherapy (Carboplatin/Cisplatin-Etoposide) and Concurrent Radiotherapy in Patients with Limited-Stage Small Cell Lung Cancer (LS-SCLC) JZP 712-402 Emerge 402: Phase IV Observational Study to Collect Safety and Outcome data in Real-World Setting in Adult Patients with Extensive Stage Small Cell Lung Cancer (SCLC) Receiving Zepzelca First Line Metastatic Mirati 849-007 A Phase 2 Trial of MRTX849 in Combination with Pembrolizumab in Patients with Advanced non-Small Cell Lung Cancer with KRAS G12C Mutation Xencor XmAb717-06 A Phase 1b/2, Open-label, Randomized Study of Vudalimab in Combination with Chemotherapy of Pembrolizumab in Combination with Chemotherapy as First-line Treatment in Patients with Advanced Non-small Cell lung Cancer Prostate D9723C00001 A Randomized, 2-cohort, Double-blind, Placebo-controlled, Phase III Study of Saruparib (AZD5305) in Combination with Physician’s choice New Hormonal Agents in Patients with HRRm and non-HRRm Metastatic Castration-Sensitive Prostate Cancer (EvoPAR-Prostate01) Solid Tumors REC-4881-221 A Phase 2, Open Label Study of REC-4881 in Participants with Unresectable Locally Advanced or Metastatic Cancer with AXIN1 or APC Mutation SGNDV-005 A Phase II Basket Study of Disitamab Vedotin in Adult Subjects with Previously Treated, Locally-Advanced Unresectable or Metastatic Solid Tumors that Express HER2 Supportive Care LP-CT-PALO-202101 A randomized, Double-Blind, Double-dummy, Parallel Group Study to Assess the Efficacy and Safety of Palonosetron HCl Buccal Film versus IV Palonosetron 0.25 mg for the Prevention of Chemotherapy-induced Nausea and Vomiting in Cancer Patients Receiving Moderately Emetogenic Chemotherapy OB202401 (Oxford Biodynamics) A Prospective Real World Evidence Study (PROWES) for concordance rate of blood- based 3D genome conformation mapping (Episwitch CiRT) to identify likelihood of response and actual response rates to PD-(L)-1 checkpoint inhibitors across multiple oncological indications TP-CA-002 Tempus Gemini NSCLC Surveillance Study A longitudinal multiomic biomarker profiling study of patients with Non-Small Cell Lung Cancer (NSCLC) TP-CA-007 Tempus Aries A Biobank Registry Platform Study in Oncology |
For more information on clinical trials, please contact Dr. Susan Johnson, Director of Research sjohnson@echoct.com or 860-886-8362.
To learn about phases of trials and what it means to participate, click here.